drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express a single CAR with tandem scFvs targeting CD19 and CD20, incorporating a 4-1BB co-stimulatory and CD3ΞΆ signaling domain to activate, expand, and mediate cytotoxic killing of malignant B cells; dual targeting aims to reduce antigen-loss escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a single CAR with tandem scFvs targeting CD19 and CD20, incorporating a 4-1BB co-stimulatory and CD3zeta signaling domain. Binding to CD19 or CD20 activates and expands the CAR T cells, driving targeted cytotoxic killing of malignant B cells and reducing antigen-loss escape.
drug_name
CD19 & CD20 bispecific CAR T cells (autologous)
nct_id_drug_ref
NCT06503094